ImageneBio (NASDAQ:IMA) Stock Rating Lowered by Wedbush

ImageneBio (NASDAQ:IMA) was downgraded by Wedbush from a “neutral” rating to an “underperform” rating in a research note issued to investors on Tuesday, November 25th, Marketbeat.com reports. Wedbush also issued estimates for ImageneBio’s Q4 2025 earnings at ($1.58) EPS, Q1 2026 earnings at ($1.62) EPS, Q2 2026 earnings at ($1.64) EPS, Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($2.02) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.95) EPS and FY2029 earnings at ($1.58) EPS.

IMA has been the subject of several other reports. Leerink Partners began coverage on ImageneBio in a research report on Friday, October 24th. They issued an “outperform” rating and a $30.00 price objective for the company. Weiss Ratings assumed coverage on shares of ImageneBio in a research report on Wednesday, October 22nd. They set a “sell (e-)” rating for the company. Wall Street Zen lowered shares of ImageneBio from a “hold” rating to a “strong sell” rating in a report on Saturday, November 15th. Leerink Partnrs raised shares of ImageneBio to a “strong-buy” rating in a research note on Friday, October 24th. Finally, Zacks Research cut ImageneBio from a “strong-buy” rating to a “hold” rating in a report on Monday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $26.50.

ImageneBio Stock Down 7.3%

Shares of IMA traded down $0.49 during trading hours on Tuesday, reaching $6.21. The stock had a trading volume of 111,644 shares, compared to its average volume of 30,220. The company has a market cap of $69.44 million, a P/E ratio of -0.77 and a beta of 0.44. ImageneBio has a 52 week low of $6.19 and a 52 week high of $23.28. The firm has a 50-day moving average of $7.90 and a 200 day moving average of $12.12.

ImageneBio (NASDAQ:IMA) last posted its earnings results on Wednesday, November 12th. The company reported ($2.91) earnings per share for the quarter, missing the consensus estimate of ($1.47) by ($1.44). As a group, equities analysts expect that ImageneBio will post -0.91 earnings per share for the current year.

Institutional Trading of ImageneBio

A number of large investors have recently added to or reduced their stakes in IMA. XTX Topco Ltd increased its stake in shares of ImageneBio by 350.6% during the 1st quarter. XTX Topco Ltd now owns 56,452 shares of the company’s stock worth $72,000 after purchasing an additional 43,924 shares during the last quarter. Aldebaran Capital LLC acquired a new stake in ImageneBio in the 1st quarter valued at about $317,000. Goldman Sachs Group Inc. grew its holdings in ImageneBio by 62.4% during the first quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company’s stock worth $98,000 after purchasing an additional 29,369 shares during the period. Vanguard Group Inc. acquired a new position in ImageneBio during the third quarter worth approximately $1,902,000. Finally, BML Capital Management LLC bought a new stake in ImageneBio in the third quarter valued at approximately $1,487,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.